Disclosure Of Interests In Other Entities [Text Block]

Innate Pharma - Filing #5981200

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—	—	—	—	—		—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	—	—	—	—	—	—	—	85 742 EUR	—	—	—	148 013 EUR	—	—	—	—	—	—	—
Non-current assets	—	—	—	—	—	—	—	25 317 EUR	—	—	—	27 175 EUR	—	—	—	—	—	—	—
Current liabilities	—	—	—	—	—	—	—	32 982 EUR	—	—	—	39 636 EUR	—	—	—	—	—	—	—
Non-current liabilities	—	—	—	—	—	—	—	69 243 EUR	—	—	—	83 650 EUR	—	—	—	—	—	—	—
Revenue	—	—	—	—	—	—	20 121 EUR	—	—	61 641 EUR	—	—	—	—	—	—	—	—	—
Profit (loss)	49 471 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	49 471 EUR	—	— EUR	7 570 EUR	7 570 EUR	—	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	—
Comprehensive income	49 471 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	49 939 EUR	—	468,000 EUR	6 900 EUR	7 570 EUR	—	994,000 EUR	— EUR	— EUR	— EUR	— EUR	324,000 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Profit (loss) from continuing operations	—	—	—	—	—	—	49 471 EUR	—	—	7 570 EUR	—	—	—	—	—	—	—	—	—
Other comprehensive income	—	—	—	—	—	—	468,000 EUR	—	—	670,000 EUR	—	—	—	—	—	—	—	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	—	—	—	—	—	—	—	66 396 EUR	—	—	—	70 605 EUR	—	—	—	—	—	—	84 225 EUR
Tax expense (income)	—	—	—	—	—	—	— EUR	—	—	— EUR	—	—	—	—	—	—	—	—	—